Sekisui Chemical Company has acquired Genzyme Corporation’s Diagnostic Product Division

Lincoln International, a leading global mid-market investment bank, has announced that Sekisui Chemical Company, the Tokyo stock exchange-listed manufacturer of a broad range of products in Japan and internationally, has completed its acquisition of Genzyme Corporation’s Diagnostic Products division for $265 million in cash.

Genzyme Diagnostics is a leading provider of global diagnostic products for diagnostics manufacturers, clinical laboratories and physician offices. Sekisui acquired facilities in the U.S., Canada, Germany and the U.K. and is retaining approximately 575 employees.

Lincoln International acted as the exclusive financial advisor to Sekisui, working closely with the senior management team throughout the sale process. This included providing advisory expertise and managing the negotiation and due diligence phases of the transaction.

Sekisui Genzyme Diagnostics Genzyme 2011
  • 2011
    Close Year
  • Healthcare
  • Public
    Client Type
  • Strategic | Cross-border
    Transaction Type
  • Japan | USA

Meet our Senior Team